S
Shumei Kato
Researcher at University of California, San Diego
Publications - 161
Citations - 6460
Shumei Kato is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 27, co-authored 113 publications receiving 4071 citations. Previous affiliations of Shumei Kato include University of California, Berkeley & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato,Aaron M. Goodman,Vighnesh Walavalkar,Donald A. Barkauskas,Andrew B. Sharabi,Razelle Kurzrock +5 more
TL;DR: Genomic profiles may help to identify patients at risk for hyperprogression on immunotherapy, and significantly increased rate of tumor growth after single-agent checkpoint (PD-1/PD-L1) inhibitors.
Journal ArticleDOI
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick,Shumei Kato,Ryosuke Okamura,Maria Schwaederle,Michael E. Hahn,Casey Williams,Pradip De,Amy Krie,David Piccioni,Vincent A. Miller,Jeffrey S. Ross,Jeffrey S. Ross,Adam Benson,Jennifer Webster,Philip J. Stephens,J. Jack Lee,Paul T. Fanta,Scott M. Lippman,Brian Leyland-Jones,Razelle Kurzrock +19 more
TL;DR: Targeting of a larger fraction of identified molecular alterations, yielding a higher ‘matching score’, was correlated with significantly improved disease control rates, as well as longer progression-free and overall survival rates, compared to targeting of fewer somatic alterations.
Journal ArticleDOI
An integrin β 3 –KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
Laetitia Seguin,Shumei Kato,Aleksandra Franovic,M. Fernanda Camargo,Jacqueline Lesperance,Kathryn C. Elliott,Mayra Yebra,Ainhoa Mielgo,Andrew M. Lowy,Hatim Husain,Tina Cascone,Lixia Diao,Jing Wang,Ignacio I. Wistuba,John V. Heymach,Scott M. Lippman,Jay S. Desgrosellier,Sudarshan Anand,Sara M. Weis,David A. Cheresh +19 more
TL;DR: It is revealed that integrin αvβ3 serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib.
Journal ArticleDOI
Novel patterns of response under immunotherapy.
Edith Borcoman,Yada Kanjanapan,Stéphane Champiat,Shumei Kato,Vincent Servois,Razelle Kurzrock,Sanjay Goel,Philippe L. Bedard,C. Le Tourneau,C. Le Tourneau +9 more
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.